Company news: Boehringer Ingelheim, GlaxoSmithKline

Share this article:
Boehringer Ingelheim's foray into oncology meds now includes a five-year collaboration agreement with personalized medicine specialist Horizon Discovery. The agreement gives Boehringer access to its Discovery Toolbox, which will profile the drug maker's compounds, and Genesis, Horizon's genome editing technology to help develop human isogenic disease model cells. Horizon said the technology will help develop “high quality cell lines” that model disease-causing mutations.

Months after its Human Genome Sciences buy, GlaxoSmithKline has submitted a BLA for albiglutide, a pipeline diabetes 2 therapy. GSK gained full ownership of the therapy with its HGS acquisition, along with ownership of Benlysta and darapladib. The experimental drug, which is being developed as a weekly shot, is a GLP-1 agonist, much like Amylin's weekly Bydureon.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.